U.S., Oct. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07219940) titled 'A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects' on Oct. 19.
Brief Summary: The investigational drug, SOB100, is an HLA-G targeted exosome equipped with a nanobody namely anti-HLA-G VHH on the exosome membrane. This is a Phase I dose escalation study to exam the tolerability, safety, and pharmacokinetics in healthy subjects.
Study Start Date: Oct., 2025
Study Type: INTERVENTIONAL
Condition:
Healthy Subjects
Exosome
Targeted Therapy
Intervention:
DRUG: SOB100
Drug: SOB100 Participants will receive SOB100 and evaluate the safety and tolerability of SOB100 during the dose escalation phase.
Recruitment...